A pilot feasibility study to assess a new therapy addresses a critical gap in treatment options for a high-risk patient population with unique emotional needs.
A new study shows that omitting aspirin from an anti-clotting regimen can improve outcomes for people living with a heart pump by reducing hospitalizations without increasing the risk of blood clots.
A new BRAIN Initiative atlas showcases the diverse cell populations within the human hypothalamus, paving the way to discovering novel cellular targets for obesity and metabolic disease
The rapid shortening of the cell's telomeres between birth and age 3 may render telomeres particularly susceptible to environmental influences during this time, potentially influencing longevity.
A new study describes multiple ways to achieve the same health benefits from exercise—as long as your exercise “cocktail” includes plenty of light physical activity.
Brief pulses of ultrasound delivered to nerves near the kidney lowered blood pressure in people with drug-resistant hypertension, Columbia and NewYork-Presbyterian physicians have found.
Scientists at Columbia took high-res images of a heat-sensing molecule in ground squirrels that could help researchers understand how we sense temperature and lead to the design of new pain relievers.
Residents of some NYC public housing developments can get free vision screening and eye exams in their building as part of a new study led by Columbia University’s Department of Ophthalmology.
A new imaging technique that can capture movies of individual receptors on the surface of living cells in unprecedented detail could pave the way to a trove of new drugs.
With $16 million gift, Columbia will open a new center for Lyme and other tick-borne diseases this summer, offering patients specialized care and expanding research at a national level.
A collaboration between Observational Health Data Sciences and Informatics (OHDSI) and Health Level Seven International (HL7) will improve access and sharing of health care data among researchers.
A clinical trial to test a gene therapy for some patients with dry age-related macular degeneration—a leading cause of blindness in the United States—is underway at Columbia and NewYork-Presbyterian.